A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

14 April, 2026

Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices

LATEST NEWS: 14 April 2026 TROG has made a

9 April, 2026

Vale Professor Jim Denham OAM, TROG founder and world-class researcher

9 April 2026 TROG Cancer Research honours the life